← All trials
NCT03274427
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 18, 2017
- Primary completion
- Jul 31, 2021
- Completion date
- Jul 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zhengzhou UniversityLead sponsor
- Zhengzhou UniversityReponsible party - principal investigator
- Zhengzhou UniversityOverall official - principal investigator
- Anyang Regional HospitalCollaborator
- Nanyang Central HospitalCollaborator
- Shenma Medical Group General HospitalCollaborator
- Xinxiang Medical UniversityCollaborator
- First People's Hospital of ShangqiuCollaborator
- Jiaozuo third people's hospitalCollaborator
- Luoyang Central HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.